REFERENCES
1. Tiwari V, Wilson DM 3rd. DNA damage and associated DNA repair defects in disease and premature aging. Am J Hum Genet 2019;105:237-57.
3. Bont R, van Larebeke N. Endogenous DNA damage in humans: a review of quantitative data. Mutagenesis 2004;19:169-85.
8. Chatterjee N, Walker GC. Mechanisms of DNA damage, repair, and mutagenesis. Environ Mol Mutagen 2017;58:235-63.
9. Pilié PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol 2019;16:81-104.
10. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell 2010;40:179-204.
11. Guirouilh-Barbat J, Lambert S, Bertrand P, Lopez BS. Is homologous recombination really an error-free process? Front Genet 2014;5:175.
12. Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Current Biol 2000;10:886-95.
13. Lanz MC, Dibitetto D, Smolka MB. DNA damage kinase signaling: checkpoint and repair at 30 years. EMBO J 2019;38:e101801.
14. Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994;266:120-2.
15. Powell SN, Kachnic LA. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 2003;22:5784-91.
16. Garfinkel DJ, Bailis AM. Nucleotide excision repair, genome stability, and human disease: new insight from model systems. J Biomed Biotechnol 2002;2:55-60.
17. Sugasawa K, Ng JM, Masutani C, et al. Xeroderma pigmentosum group C protein complex is the initiator of global genome nucleotide excision repair. Mol Cell 1998;2:223-32.
18. Henning KA, Li L, Iyer N, et al. The cockayne syndrome group a gene encodes a WD repeat protein that interacts with CSB protein and a subunit of RNA polymerase II TFIIH. Cell 1995;82:555-64.
19. Mellon I. Selective removal of transcription-blocking DNA damage from the transcribed strand of the mammalian DHFR gene. Cell 1987;51:241-9.
20. van Gool AJ, Citterio E, Rademakers S, et al. The Cockayne syndrome B protein, involved in transcription-coupled DNA repair, resides in an RNA polymerase II-containing complex. EMBO J 1997;16:5955-65.
21. Kraemer KH, Lee MM, Scotto J. DNA repair protects against cutaneous and internal neoplasia: evidence from xeroderma pigmentosum. Carcinogenesis 1984;5:511-4.
22. Wilson BT, Stark Z, Sutton RE, et al. The Cockayne Syndrome Natural History (CoSyNH) study: clinical findings in 102 individuals and recommendations for care. Genet Med 2016;18:483-93.
24. Mol CD, Parikh SS, Putnam CD, Lo TP, Tainer JA. DNA repair mechanisms for the recognition and removal of damaged DNA bases. Annu Rev Biophys Biomol Struct 1999;28:101-28.
25. Divine KK, Gilliland FD, Crowell RE, et al. The XRCC1 399 glutamine allele is a risk factor for adenocarcinoma of the lung. Mutat Res/DNA Rep 2001;461:273-8.
27. Umar A, Buermeyer AB, Simon JA, et al. Requirement for PCNA in DNA mismatch repair at a step preceding DNA resynthesis. Cell 1996;87:65-73.
29. Jiricny J, Nyström-lahti M. Mismatch repair defects in cancer. Curr Opin Genet Dev 2000;10:157-61.
30. Knipscheer P, Räschle M, Smogorzewska A, et al. The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science 2009;326:1698-701.
31. Moldovan GL, D’Andrea AD. How the fanconi anemia pathway guards the genome. Annu Rev Genet 2009;43:223-49.
32. Ceccaldi R, Sarangi P, D’Andrea AD. The Fanconi anaemia pathway: new players and new functions. Nat Rev Mol Cell Biol 2016;17:337-49.
33. Chen HT, Bhandoola A, Difilippantonio MJ, et al. Response to RAG-mediated VDJ cleavage by NBS1 and gamma-H2AX. Science 2000;290:1962-5.
34. Bassing CH, Alt FW. The cellular response to general and programmed DNA double strand breaks. DNA Repair (Amst) 2004;3:781-96.
35. Moshous D, Callebaut I, de Chasseval R, et al. Artemis, a novel DNA Double-Strand Break Repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. Cell 2001;105:177-86.
36. Keeney S, Giroux CN, Kleckner N. Meiosis-Specific DNA double-strand breaks are catalyzed by spo11, a member of a widely conserved protein family. Cell 1997;88:375-84.
37. Neale MJ, Keeney S. Clarifying the mechanics of DNA strand exchange in meiotic recombination. Nature 2006;442:153-8.
38. Richardson C, Horikoshi N, Pandita TK. The role of the DNA double-strand break response network in meiosis. DNA Repair (Amst) 2004;3:1149-64.
40. Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 2005;19:2100-10.
41. di Fagagna F, Teo SH, Jackson SP. Functional links between telomeres and proteins of the DNA-damage response. Genes Dev 2004;18:1781-99.
43. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009;461:1071-8.
44. Longhese MP. DNA damage response at functional and dysfunctional telomeres. Genes Dev 2008;22:125-40.
45. Sedelnikova OA, Horikawa I, Zimonjic DB, Popescu NC, Bonner WM, Barrett JC. Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks. Nat Cell Biol 2004;6:168-70.
46. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability - an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010;11:220-8.
48. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-33.
49. Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007;7:937-48.
50. Kote-Jarai Z, Leongamornlert D, Saunders E, et al. UKGPCS Collaborators. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer 2011;105:1230-4.
51. Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2007;99:1811-4.
52. Ibrahim M, Yadav S, Ogunleye F, Zakalik D. Male BRCA mutation carriers: clinical characteristics and cancer spectrum. BMC Cancer 2018;18:179.
53. Levy-Lahad E. Fanconi anemia and breast cancer susceptibility meet again. Nat Genet 2010;42:368-9.
55. Spry M, Scott T, Pierce H, D’Orazio JA. DNA repair pathways and hereditary cancer susceptibility syndromes. Front Biosci 2007;12:4191-207.
56. Nalepa G, Clapp DW. Fanconi anaemia and cancer: an intricate relationship. Nat Rev Cancer 2018;18:168-85.
57. Chan SH, Ni Y, Li S, et al. Spectrum of germline mutations within fanconi anemia–associated genes across populations of varying ancestry. JNCI Cancer Spectrum 2021;5:pkaa117.
58. Ruggeri B, DiRado M, Zhang SY, Bauer B, Goodrow T, Klein-Szanto AJ. Benzo[a]pyrene-induced murine skin tumors exhibit frequent and characteristic G to T mutations in the p53 gene. Proc Natl Acad Sci USA 1993;90:1013-7.
60. Lomax ME, Folkes LK, O’Neill P. Biological consequences of radiation-induced DNA damage: relevance to radiotherapy. Clin Oncol (R Coll Radiol) 2013;25:578-85.
61. D’Errico M, Parlanti E, Teson M, et al. New functions of XPC in the protection of human skin cells from oxidative damage. EMBO J 2006;25:4305-15.
62. Kraemer KH, DiGiovanna JJ. Forty years of research on xeroderma pigmentosum at the US National Institutes of Health. Photochem Photobiol 2015;91:452-9.
63. Carpenter DO, Bushkin-Bedient S. Exposure to chemicals and radiation during childhood and risk for cancer later in life. J Adolesc Health 2013;52:S21-9.
64. Rass U, Ahel I, West SC. Defective DNA repair and neurodegenerative disease. Cell 2007;130:991-1004.
65. Welty S, Teng Y, Liang Z, et al. RAD52 is required for RNA-templated recombination repair in post-mitotic neurons. J Biol Chem 2018;293:1353-62.
66. Madabhushi R, Pan L, Tsai LH. DNA damage and its links to neurodegeneration. Neuron 2014;83:266-82.
67. Biton S, Barzilai A, Shiloh Y. The neurological phenotype of ataxia-telangiectasia: solving a persistent puzzle. DNA Repair (Amst) 2008;7:1028-38.
68. O’Driscoll M, Jeggo PA. The role of the DNA damage response pathways in brain development and microcephaly: insight from human disorders. DNA Repair (Amst) 2008;7:1039-50.
69. Kerzendorfer C, O’Driscoll M. Human DNA damage response and repair deficiency syndromes: linking genomic instability and cell cycle checkpoint proficiency. DNA Repair (Amst) 2009;8:1139-52.
70. Katyal S, McKinnon PJ. DNA strand breaks, neurodegeneration and aging in the brain. Mech Ageing Dev 2008;129:483-91.
71. Waltes R, Kalb R, Gatei M, et al. Human RAD50 deficiency in a Nijmegen breakage syndrome-like disorder. Am J Hum Genet 2009;84:605-16.
72. Shull ER, Lee Y, Nakane H, et al. Differential DNA damage signaling accounts for distinct neural apoptotic responses in ATLD and NBS. Genes Dev 2009;23:171-80.
73. Otake M, Schull WJ. Radiation-related brain damage and growth retardation among the prenatally exposed atomic bomb survivors. Int J Radiat Biol 1998;74:159-71.
74. Reynolds JJ, Stewart GS. A single strand that links multiple neuropathologies in human disease. Brain 2013;136:14-27.
75. Takashima H, Boerkoel CF, John J, et al. Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy. Nat Genet 2002;32:267-72.
76. El-Khamisy SF, Saifi GM, Weinfeld M, et al. Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature 2005;434:108-13.
77. Moreira MC, Barbot C, Tachi N, et al. The gene mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn-finger protein aprataxin. Nat Genet 2001;29:189-93.
78. Inlora J, Sailani MR, Khodadadi H, et al. Identification of a novel mutation in the. APTX ;3:a002014.
79. Harris JL, Jakob B, Taucher-Scholz G, Dianov GL, Becherel OJ, Lavin MF. Aprataxin, poly-ADP ribose polymerase 1 (PARP-1) and apurinic endonuclease 1 (APE1) function together to protect the genome against oxidative damage. Hum Mol Genet 2009;18:4102-17.
80. Seidle HF, Bieganowski P, Brenner C. Disease-associated mutations inactivate AMP-lysine hydrolase activity of Aprataxin. J Biol Chem 2005;280:20927-31.
81. Hoch NC, Hanzlikova H, Rulten SL, et al. Care4Rare Canada Consortium. XRCC1 mutation is associated with PARP1 hyperactivation and cerebellar ataxia. Nature 2017;541:87-91.
83. Tilgner K, Neganova I, Singhapol C, et al. Brief report: a human induced pluripotent stem cell model of cernunnos deficiency reveals an important role for XLF in the survival of the primitive hematopoietic progenitors. Stem Cells 2013;31:2015-23.
84. Guo C, Nakazawa Y, Woodbine L, et al. XRCC4 deficiency in human subjects causes a marked neurological phenotype but no overt immunodeficiency. J Allergy Clin Immunol 2015;136:1007-17.
85. Kennedy BK, Berger SL, Brunet A, et al. Geroscience: linking aging to chronic disease. Cell 2014;159:709-13.
86. Natale V. A comprehensive description of the severity groups in Cockayne syndrome. Am J Med Genet A 2011;155A:1081-95.
87. Laugel V. Cockayne syndrome: the expanding clinical and mutational spectrum. Mech Ageing Dev 2013;134:161-70.
88. Andressoo JO, Hoeijmakers JH. Transcription-coupled repair and premature ageing. Mutat Res 2005;577:179-94.
89. Vermeulen W, Rademakers S, Jaspers NG, et al. A temperature-sensitive disorder in basal transcription and DNA repair in humans. Nat Genet 2001;27:299-303.
90. de Boer J, Andressoo JO, de Wit J, et al. Premature aging in mice deficient in DNA repair and transcription. Science 2002;296:1276-9.
91. Wijnhoven SW, Beems RB, Roodbergen M, et al. Accelerated aging pathology in ad libitum fed Xpd(TTD) mice is accompanied by features suggestive of caloric restriction. DNA Repair (Amst) 2005;4:1314-24.
92. van der Pluijm I, Garinis GA, Brandt RM, et al. Impaired genome maintenance suppresses the growth hormone - insulin-like growth factor 1 axis in mice with Cockayne syndrome. PLoS Biol 2007;5:e2.
93. Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol 1987;123:241-50.
94. Brooks PJ. The 8,5’-cyclopurine-2’-deoxynucleosides: candidate neurodegenerative DNA lesions in xeroderma pigmentosum, and unique probes of transcription and nucleotide excision repair. DNA Repair (Amst) 2008;7:1168-79.
95. Sidorova JM, Monnat RJ. Human RECQ helicases: roles in cancer, aging, and inherited disease. Adv Genomics Genet 2014;5:19-33.
96. Root H, Larsen A, Komosa M, et al. FANCD2 limits BLM-dependent telomere instability in the alternative lengthening of telomeres pathway. Hum Mol Genet 2016;25:3255-68.
97. Wietmarschen N, Merzouk S, Halsema N, Spierings DCJ, Guryev V, Lansdorp PM. BLM helicase suppresses recombination at G-quadruplex motifs in transcribed genes. Nat Commun 2018;9:271.
98. Luong TT, Bernstein KA. Role and regulation of the RECQL4 family during genomic integrity maintenance. Genes (Basel) 2021;12:1919.
99. Liu FJ, Barchowsky A, Opresko PL. The Werner syndrome protein suppresses telomeric instability caused by chromium (VI) induced DNA replication stress. PLoS ONE 2010;5:e11152.
100. Hanada K, Hickson ID. Molecular genetics of RecQ helicase disorders. Cell Mol Life Sci 2007;64:2306-22.
101. Croteau DL, Singh DK, Hoh Ferrarelli L, Lu H, Bohr VA. RECQL4 in genomic instability and aging. Trends Genet 2012;28:624-31.
102. Kudlow BA, Kennedy BK, Monnat RJ Jr. Werner and Hutchinson-Gilford progeria syndromes: mechanistic basis of human progeroid diseases. Nat Rev Mol Cell Biol 2007;8:394-404.
103. Schatz DG, Ji Y. Recombination centres and the orchestration of V(D)J recombination. Nat Rev Immunol 2011;11:251-63.
104. Villartay JP, Fischer A, Durandy A. The mechanisms of immune diversification and their disorders. Nat Rev Immunol 2003;3:962-72.
105. Bohgaki M, Bohgaki T, El Ghamrasni S, et al. RNF168 ubiquitylates 53BP1 and controls its response to DNA double-strand breaks. Proc Natl Acad Sci USA 2013;110:20982-7.
106. Lieber MR. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem 2010;79:181-211.
107. Keim C, Kazadi D, Rothschild G, Basu U. Regulation of AID, the B-cell genome mutator. Genes Dev 2013;27:1-17.
108. Villartay J, Poinsignon C, de Chasseval R, Buck D, Le Guyader G, Villey I. Human and animal models of V(D)J recombination deficiency. Curr Opin Immunol 2003;15:592-8.
110. Felgentreff K, Lee YN, Frugoni F, et al. Functional analysis of naturally occurring DCLRE1C mutations and correlation with the clinical phenotype of ARTEMIS deficiency. J Allergy Clin Immunol 2015;136:140-150.e7.
111. Durandy A, Taubenheim N, Peron S, Fischer A. Pathophysiology of B-cell intrinsic immunoglobulin class switch recombination deficiencies. Adv Immunol 2007;94:275-306.
113. Casellas R, Basu U, Yewdell WT, Chaudhuri J, Robbiani DF, Di Noia JM. Mutations, kataegis and translocations in B cells: understanding AID promiscuous activity. Nat Rev Immunol 2016;16:164-76.
114. Kracker S, Gardës P, Durandy A. Inherited defects of immunoglobulin class switch recombination. Adv Exp Med Biol 2010;685:166-74.
115. Wimmer K, Kratz CP, Vasen HF, et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium ‘care for CMMRD’ (C4CMMRD). J Med Genet 2014;51:355-65.
116. Stewart GS, Panier S, Townsend K, et al. The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damage. Cell 2009;136:420-34.
117. Chrzanowska KH, Gregorek H, Dembowska-Bagińska B, Kalina MA, Digweed M. Nijmegen breakage syndrome (NBS). Orphanet J Rare Dis 2012;7:13.
118. Specks J, Nieto-soler M, Lopez-contreras AJ, Fernandez-capetillo O. Modeling the study of DNA damage responses in mice. Methods Mol Biol 2015;1267:413-37.
119. Elson A, Wang Y, Daugherty CJ, et al. Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. Proc Natl Acad Sci USA 1996;93:13084-9.
120. Herzog KH, Chong MJ, Kapsetaki M, Morgan JI, McKinnon PJ. Requirement for Atm in ionizing radiation-induced cell death in the developing central nervous system. Science 1998;280:1089-91.
121. Xu Y, Baltimore D. Dual roles of ATM in the cellular response to radiation and in cell growth control. Genes Dev 1996;10:2401-10.
122. Spring K, Cross S, Li C, et al. Atm knock-in mice harboring an in-frame deletion corresponding to the human ATM 7636del9 common mutation exhibit a variant phenotype. Cancer Res 2001;61:4561-68.
123. Tal E, Alfo M, Zha S, et al. Inactive Atm abrogates DSB repair in mouse cerebellum more than does Atm loss, without causing a neurological phenotype. DNA Repair (Amst) 2018;72:10-7.
124. Lavin MF. The appropriateness of the mouse model for ataxia-telangiectasia: neurological defects but no neurodegeneration. DNA Repair (Amst) 2013;12:612-9.
125. Perez H, Abdallah MF, Chavira JI, et al. A novel, ataxic mouse model of ataxia telangiectasia caused by a clinically relevant nonsense mutation. Elife 2021;10:e64695.
126. Hakem R, de la Pompa JL, Sirard C, et al. The Tumor Suppressor Gene Brca1 Is Required for Embryonic Cellular Proliferation in the Mouse. Cell 1996;85:1009-23.
127. Liu X, Holstege H, van der Gulden H, et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci USA 2007;104:12111-6.
128. Xu X, Wagner KU, Larson D, et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 1999;22:37-43.
129. Drost R, Bouwman P, Rottenberg S, et al. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell 2011;20:797-809.
130. Wind N, Dekker M, Berns A, Radman M, te Riele H. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell 1995;82:321-30.
131. Wind N, Dekker M, van Rossum A, van der Valk M, Te Riele H. Mouse models for hereditary nonpolyposis colorectal cancer. Cancer Res 1998;58:248-255.
132. Chester N, Kuo F, Kozak C, O’Hara CD, Leder P. Stage-specific apoptosis, developmental delay, and embryonic lethality in mice homozygous for a targeted disruption in the murine Bloom’s syndrome gene. Genes Dev 1998;12:3382-93.
133. Cheng NC, van de Vrugt HJ, van der Valk MA, et al. Mice with a targeted disruption of the Fanconi anemia homolog Fanca. Hum Mol Genet 2000;9:1805-11.
134. Whitney MA, Royle G, Low MJ, et al. Germ cell defects and hematopoietic hypersensitivity to gamma-interferon in mice with a targeted disruption of the Fanconi anemia C gene. Blood 1996;88:49-58.
135. Carreau M, Gan OI, Liu L, Doedens M, McKerlie C, Dick JE. Bone marrow failure in the Fanconi anemia group C mouse model after DNA damage. Blood 1998;91:2737-44.
136. Chang S, Multani AS, Cabrera NG, et al. Essential role of limiting telomeres in the pathogenesis of Werner syndrome. Nat Genet 2004;36:877-82.
137. Eriksson M, Brown WT, Gordon LB, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003;423:293-8.
138. Liu B, Wang J, Chan KM, et al. Genomic instability in laminopathy-based premature aging. Nat Med 2005;11:780-5.
139. Alderton GK, Joenje H, Varon R, Børglum AD, Jeggo PA, O’Driscoll M. Seckel syndrome exhibits cellular features demonstrating defects in the ATR-signalling pathway. Hum Mol Genet 2004;13:3127-38.
140. Murga M, Bunting S, Montaña MF, et al. A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging. Nat Genet 2009;41:891-8.
141. Murai M, Enokido Y, Inamura N, et al. Early postnatal ataxia and abnormal cerebellar development in mice lacking Xeroderma pigmentosum Group A and Cockayne syndrome Group B DNA repair genes. Proc Natl Acad Sci USA 2001;98:13379-84.
142. Van der Horst GT, van Steeg H, Berg RJ, et al. Defective Transcription-Coupled Repair in Cockayne Syndrome B Mice Is Associated with Skin Cancer Predisposition. Cell 1997;89:425-35.
143. Zhu J, Petersen S, Tessarollo L, Nussenzweig A. Targeted disruption of the Nijmegen breakage syndrome gene NBS1 leads to early embryonic lethality in mice. Curr Biol 2001;11:105-9.
144. Kang J, Bronson RT, Xu Y. Targeted disruption of NBS1 reveals its roles in mouse development and DNA repair. EMBO J 2002;21:1447-55.
145. Frappart PO, Tong WM, Demuth I, et al. An essential function for NBS1 in the prevention of ataxia and cerebellar defects. Nat Med 2005;11:538-44.
146. Yang YG, Frappart PO, Frappart L, Wang ZQ, Tong WM. A novel function of DNA repair molecule Nbs1 in terminal differentiation of the lens fibre cells and cataractogenesis. DNA Repair (Amst) 2006;5:885-93.
147. Assaf Y, Galron R, Shapira I, et al. MRI evidence of white matter damage in a mouse model of Nijmegen breakage syndrome. Exp Neurol 2008;209:181-91.
148. Baranes K, Raz-Prag D, Nitzan A, et al. Conditional inactivation of the NBS1 gene in the mouse central nervous system leads to neurodegeneration and disorganization of the visual system. Exp Neurol 2009;218:24-32.
149. Galron R, Gruber R, Lifshitz V, et al. Astrocyte dysfunction associated with cerebellar attrition in a Nijmegen breakage syndrome animal model. J Mol Neurosci 2011;45:202-11.
150. Martin LJ, Chang Q. DNA damage response and repair, DNA methylation, and cell death in human neurons and experimental animal neurons are different. J Neuropathol Exp Neurol 2018;77:636-55.
151. Li J, Pan L, Pembroke WG, et al. Conservation and divergence of vulnerability and responses to stressors between human and mouse astrocytes. Nat Commun 2021;12:3958.
152. Gatti RA. Ataxia Telangiectasia. 600-606 (Lippincott Williams & Wilkins, 2003). Available from: https://www.derm.theclinics.com/article/S0733-8635(18)30100-1/pdf [Last accessed on 9 May 2022].
153. Stewart GS, Maser RS, Stankovic T, et al. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell 1999;99:577-87.
154. Gennery AR, Cant AJ, Jeggo PA. Immunodeficiency associated with DNA repair defects. Clin Exp Immunol 2000;121:1-7.
155. Niraj J, Färkkilä A, D’Andrea AD. The Fanconi anemia pathway in cancer. Annu Rev Cancer Biol 2019;3:457-78.
156. Katsuki Y, Takata M. Defects in homologous recombination repair behind the human diseases: FA and HBOC. Endocr Relat Cancer 2016;23:T19-37.
157. Prakash R, Zhang Y, Feng W, Jasin M. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol 2015;7:a016600.
158. Fishel R, Lescoe MK, Rao M, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993;75:1027-38.
159. Parsons R, Li G, Longley MJ, et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 1993;75:1227-36.
160. Ryan E, Sheahan K, Creavin B, Mohan HM, Winter DC. The current value of determining the mismatch repair status of colorectal cancer: A rationale for routine testing. Crit Rev Oncol Hematol 2017;116:38-57.
161. de Andrade KC, Frone MN, Wegman-Ostrosky T, et al. Variable population prevalence estimates of germline TP53 variants: a gnomAD-based analysis. Hum Mutat 2019;40:97-105.
162. Wiesmüller L, Ford JM, Schiestl RH. DNA damage, repair, and diseases. J Biomed Biotechnol 2002;2:45.
163. Al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MYH associated with somatic G:C-->T:A mutations in colorectal tumors. Nat Genet 2002;30:227-32.
164. Weren RD, Ligtenberg MJ, Kets CM, et al. A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nat Genet 2015;47:668-71.
165. Grover S, Kastrinos F, Steyerberg EW, et al. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA 2012;308:485-92.
166. Carney JP, Maser RS, Olivares H, et al. The hMre11/hRad50 protein complex and nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell 1998;93:477-86.
167. Matsuura S, Tauchi H, Nakamura A, et al. Positional cloning of the gene for Nijmegen breakage syndrome. Nat Genet 1998;19:179-81.
168. Oshima J, Sidorova JM, Monnat RJ Jr. Werner syndrome: clinical features, pathogenesis and potential therapeutic interventions. Ageing Res Rev 2017;33:105-14.
170. Lehmann J, Seebode C, Martens MC, Emmert S. Xeroderma pigmentosum - facts and perspectives. Anticancer Res 2018;38:1159-64.
171. Sharma R, Lewis S, Wlodarski MW. DNA repair syndromes and cancer: insights Into genetics and phenotype patterns. Front Pediatr 2020;8:570084.
173. Livingston JH, Crow YJ. Neurologic phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1, and IFIH1: aicardi-goutières syndrome and beyond. Neuropediatrics 2016;47:355-60.
175. Anheim M, Monga B, Fleury M, et al. Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients. Brain 2009;132:2688-98.
176. Laugel V, Dalloz C, Tobias ES, et al. Cerebro-oculo-facio-skeletal syndrome: three additional cases with CSB mutations, new diagnostic criteria and an approach to investigation. J Med Genet 2008;45:564-71.
177. Le Van Quyen P, Calmels N, Bonnière M, et al. Prenatal diagnosis of cerebro-oculo-facio-skeletal syndrome: Report of three fetuses and review of the literature. Am J Med Genet A 2020;182:1236-42.
178. Karikkineth AC, Scheibye-Knudsen M, Fivenson E, Croteau DL, Bohr VA. Cockayne syndrome: clinical features, model systems and pathways. Ageing Res Rev 2017;33:3-17.
180. Dumitrache LC, McKinnon PJ. Polynucleotide kinase-phosphatase (PNKP) mutations and neurologic disease. Mech Ageing Dev 2017;161:121-9.
181. Reynolds JJ, Walker AK, Gilmore EC, Walsh CA, Caldecott KW. Impact of PNKP mutations associated with microcephaly, seizures and developmental delay on enzyme activity and DNA strand break repair. Nucleic Acids Res 2012;40:6608-19.
182. Shen J, Gilmore EC, Marshall CA, et al. Mutations in PNKP cause microcephaly, seizures and defects in DNA repair. Nat Genet 2010;42:245-9.
183. O’Driscoll M, Ruiz-Perez VL, Woods CG, Jeggo PA, Goodship JA. A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat Genet 2003;33:497-501.
184. Saneto RP, Cohen BH, Copeland WC, Naviaux RK. Alpers-Huttenlocher syndrome. Pediatr Neurol 2013;48:167-78.
185. Harhouri K, Frankel D, Bartoli C, Roll P, De Sandre-Giovannoli A, Lévy N. An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome. Nucleus 2018;9:246-57.
186. Hennekam RC. Hutchinson-Gilford progeria syndrome: review of the phenotype. Am J Med Genet A 2006;140:2603-24.
187. Morio T. Recent advances in the study of immunodeficiency and DNA damage response. Int J Hematol 2017;106:357-65.
